Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update

Figure 1 Factors that contribute to the pathogenesis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; TNF-α: Tumor necrosis factor-alpha; CYP2E1: Cytochrome P450 2E1; FFA: Free fatty acid; NF-κB: Nuclear factor kappa-light-chain-enhancer.

Figure 2 Liver biopsy of a patients with non-alcoholic steatohepatitis at baseline (A) and one year after 10 mg/d of rosuvastatin monotherapy (B) [unpublished data from personal archive].